OS Therapies Terminates At Market Issuance Sales Agreement On July 23; Co. Announces Termination Of Sales Agreement Effective July 28
OS Therapies Inc OSTX
$1.52
▼ -2.56%
($-0.04)
Open
$1.58
Prev Close
$1.56
Day Range
$1.51 – $1.61
52W Range
$1.15 – $2.57
Market Cap
$69.22M
Beta
1.34
EPS (TTM)
$-1.05
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2024-08-01 |
| Shares Out. | 45,540,000 |
| Website | ostherapies.com/ ↗ |
| Phone | 14102977793 |
| Employees | 5 |
| Net Income | -$10.4M |
| Free Cash Flow | -$15.8M |
| Total Assets | $7.3M |
| Total Liabilities | $17.1M |
| Equity | -$10.8M |
About OS Therapies Inc
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
OS Therapies Inc is a publicly traded company under the ticker symbol OSTX on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)